Savient Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

SVNTQ 0.0019
price chart
Bridgewater-based Savient Pharmaceuticals OKd for Chapter 11 plan
Savient Pharmaceuticals Inc., a developer of a treatment for gout before its business was sold, got approval of a liquidating Chapter 11 plan, with U.S.
Savient Pharmaceuticals gets approval from US Bankruptcy Court to sell all ...
Savient Pharmaceuticals filed for bankruptcy in October. Citing a filing in the Bankruptcy Court in Wilmington, Delaware, Bloomberg reported that Savient had debts amounting to $260 million and only had assets of $74 million.
Bankrupt Savient Gets OK For $120M Sale To Crealta  Law360 (subscription)
Savient Receives Approval From Bankruptcy Court To Sell Substantially All ...  PR Newswire (press release)
Related articles »  
Savient Pharmaceuticals: Is Anything Left?
Savient Pharmaceuticals (SVNT) has been on a roller-coater ride since the approval of its drug Krystexxa for refractory chronic gout.
Trying to Get a Handle on Savient Pharmaceuticals' Valuation
Savient (SVNT) announced in May that it would try to find a buyer after its gout drug, Krystexxa, gained FDA approval. That day finally came Sept.
Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity
I am recommending purchase of Savient Pharmaceuticals (SVNT) at the current price of around $2.35. My recommendation is based on the estimate that Krystexxa sales could reach $209 million in 2015 and my valuation methodology suggests that the stock ...
Savient Pharma: Still Struggling To Grow KRYSTEXXA Sales
After reporting Q3 earnings, Savient Pharma (SVNT) plummeted back to a $1 from the meteoric rise to nearly $3 during the quarter.
Gout Drug's Sales Flop Lands Savient Pharma in Chapter 11
Three years ago, Savient Pharmaceuticals (NASDAQ: SVNT) was riding an FDA-approved gout drug to a stock price in the $20s. Now, its best hope to avoid an outright liquidation is a bankruptcy sale.
Related articles »  
Crealta Pharmaceuticals LLC Announces Completion of the Acquisition of ...
GLENDALE, Wis., Jan. 10, 2014 /PRNewswire/ -- Crealta Pharmaceuticals LLC ("Crealta"), a new specialty pharmaceutical company, announced today the completion of the acquisition of substantially all of the assets of Savient Pharmaceuticals, Inc.
Related articles »  
Savient: The Tang Rally Is Over - What's Next
Savient Pharmaceuticals (SVNT) has experienced a dramatic recovery since early August. We believe that the investment thesis for SVNT has now changed.
GTCR's Crealta To Buy Savient Pharmaceuticals
By Ben Fox Rubin. Biopharmaceutical firm Savient Pharmaceuticals agreed to sell itself to Crealta Pharmaceuticals LLC for $120.4 million, following a bankruptcy-court approved auction.
Savient Pharma Sells to GTCR-Backed Crealta For $120M  Xconomy
Savient acquired by Crealta Pharmaceuticals in $120M bankruptcy auction  NJBIZ
Related articles »